PURPOSE: We evaluated whether (18)F-3'-deoxy-3'-fluorothymidine positron emission tomography (FLT PET) can predict the final postoperative histopathological response in primary breast cancer after the first cycle of neoadjuvant chemotherapy (NCT). METHODS: In this prospective cohort study of 15 patients with locally advanced operable breast cancer, FLT PET evaluations were performed before NCT, after the first cycle of NCT, and at the end of NCT. All patients subsequently underwent surgery. Variables from FLT PET examinations were correlated with postoperative histopathological results. RESULTS: At baseline, median of maximum standardized uptake values (SUVmax) in the groups showing a complete pathological response (pCR) + residual cancer burden (RCB) I, RCB II or RCB III did not differ significantly for the primary tumour (5.0 vs. 2.9 vs. 8.9, p = 0.293) or for axillary nodes (7.9 vs. 1.6 vs. 7.0, p = 0.363), whereas the Spearman correlation between SUVmax and Ki67 proliferation rate index was significant (r = 0.69, p < 0.001). Analysis of the relative percentage change of SUVmaxin the primary tumour (∆SUVTmax(t₁)) and axillary nodes (∆SUVNmax(t₁)) after the first NCT cycle showed that the power of ∆SUVTmax(t 1) to predict pCR + RCB I responses (AUC = 0.91, p < 0.001) was statistically significant, whereas ∆SUVNmax(t₁) had a moderate ability (AUC = 0.77, p = 0.119) to separate subjects with ΔSUVTmax(t₁) > -52.9 % into two groups: RCB III patients and a heterogeneous group that included RCB I and RCB II patients. A predictive score μ based on ΔSUVTmax(t₁) and ΔSUVNmax(t₁) parameters is proposed. CONCLUSION: The preliminary findings of the present study suggest the potential utility of FLT PET scans for early monitoring of response to NCT and to formulate a therapeutic strategy consistent with the estimated efficacy of NCT. However, these results in a small patient population need to be validated in a larger independent cohort.
PURPOSE: We evaluated whether (18)F-3'-deoxy-3'-fluorothymidine positron emission tomography (FLT PET) can predict the final postoperative histopathological response in primary breast cancer after the first cycle of neoadjuvant chemotherapy (NCT). METHODS: In this prospective cohort study of 15 patients with locally advanced operable breast cancer, FLT PET evaluations were performed before NCT, after the first cycle of NCT, and at the end of NCT. All patients subsequently underwent surgery. Variables from FLT PET examinations were correlated with postoperative histopathological results. RESULTS: At baseline, median of maximum standardized uptake values (SUVmax) in the groups showing a complete pathological response (pCR) + residual cancer burden (RCB) I, RCB II or RCB III did not differ significantly for the primary tumour (5.0 vs. 2.9 vs. 8.9, p = 0.293) or for axillary nodes (7.9 vs. 1.6 vs. 7.0, p = 0.363), whereas the Spearman correlation between SUVmax and Ki67 proliferation rate index was significant (r = 0.69, p < 0.001). Analysis of the relative percentage change of SUVmaxin the primary tumour (∆SUVTmax(t₁)) and axillary nodes (∆SUVNmax(t₁)) after the first NCT cycle showed that the power of ∆SUVTmax(t 1) to predict pCR + RCB I responses (AUC = 0.91, p < 0.001) was statistically significant, whereas ∆SUVNmax(t₁) had a moderate ability (AUC = 0.77, p = 0.119) to separate subjects with ΔSUVTmax(t₁) > -52.9 % into two groups: RCB III patients and a heterogeneous group that included RCB I and RCB II patients. A predictive score μ based on ΔSUVTmax(t₁) and ΔSUVNmax(t₁) parameters is proposed. CONCLUSION: The preliminary findings of the present study suggest the potential utility of FLT PET scans for early monitoring of response to NCT and to formulate a therapeutic strategy consistent with the estimated efficacy of NCT. However, these results in a small patient population need to be validated in a larger independent cohort.
Authors: David Groheux; Elif Hindié; Sylvie Giacchetti; Anne-Sophie Hamy; Frederique Berger; Pascal Merlet; Anne de Roquancourt; Patricia de Cremoux; Michel Marty; Mathieu Hatt; Marc Espié Journal: Eur J Cancer Date: 2014-05-16 Impact factor: 9.162
Authors: Michael A Jacobs; Ronald Ouwerkerk; Antonio C Wolff; Edward Gabrielson; Hind Warzecha; Stacie Jeter; David A Bluemke; Richard Wahl; Vered Stearns Journal: Breast Cancer Res Treat Date: 2011-04-01 Impact factor: 4.872
Authors: O Humbert; A Berriolo-Riedinger; J M Riedinger; B Coudert; L Arnould; A Cochet; C Loustalot; P Fumoleau; F Brunotte Journal: Ann Oncol Date: 2012-04-12 Impact factor: 32.976
Authors: Sina Meisamy; Patrick J Bolan; Eva H Baker; Robin L Bliss; Evin Gulbahce; Lenore I Everson; Michael T Nelson; Tim H Emory; Todd M Tuttle; Douglas Yee; Michael Garwood Journal: Radiology Date: 2004-11 Impact factor: 11.105
Authors: W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai Journal: J Clin Oncol Date: 2007-09-04 Impact factor: 44.544
Authors: Andreas K Buck; Holger Schirrmeister; Martin Hetzel; Mareike Von Der Heide; Gisela Halter; Gerhard Glatting; Torsten Mattfeldt; Florian Liewald; Sven N Reske; Bernd Neumaier Journal: Cancer Res Date: 2002-06-15 Impact factor: 12.701
Authors: E Provenzano; A-L Vallier; R Champ; K Walland; S Bowden; A Grier; N Fenwick; J Abraham; M Iddawela; C Caldas; L Hiller; J Dunn; H M Earl Journal: Br J Cancer Date: 2013-01-08 Impact factor: 7.640
Authors: Benjamin E Ueberroth; Jawana M Lawhorn-Crews; Lance K Heilbrun; Daryn W Smith; Janice Akoury; Rouba Ali-Fehmi; Nicole T Eiseler; Anthony F Shields Journal: Ann Nucl Med Date: 2019-02-27 Impact factor: 2.668
Authors: Kibo Nam; John R Eisenbrey; Maria Stanczak; Anush Sridharan; Adam C Berger; Tiffany Avery; Juan P Palazzo; Flemming Forsberg Journal: Radiology Date: 2017-05-03 Impact factor: 11.105
Authors: G M Kramer; Y Liu; A J de Langen; E P Jansma; I Trigonis; M-C Asselin; A Jackson; L Kenny; E O Aboagye; O S Hoekstra; R Boellaard Journal: Eur J Nucl Med Mol Imaging Date: 2018-01-23 Impact factor: 9.236
Authors: Lorenzo Fantini; Maria Luisa Belli; Irene Azzali; Emiliano Loi; Andrea Bettinelli; Giacomo Feliciani; Emilio Mezzenga; Anna Fedeli; Silvia Asioli; Giovanni Paganelli; Anna Sarnelli; Federica Matteucci Journal: Front Oncol Date: 2021-06-24 Impact factor: 6.244